Download PDF

1. Company Snapshot

1.a. Company Description

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.


The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder.The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc.Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Show Full description

1.b. Last Insights on JAZZ

Jazz Pharmaceuticals' recent performance was driven by strong Q3 earnings, with quarterly earnings of $8.13 per share beating estimates. The company's diversified portfolio showed robust growth, particularly in Epidiolex, Xywav, and the launch of Modeyso. Additionally, positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer and upgraded 2025 revenue guidance further bolstered the company's prospects. A BUY rating was assigned by some analysts, citing strong DUET trial results and growth anchored by Xywav and Epidiolex.

1.c. Company Highlights

2. Jazz Pharmaceuticals' Q3 2025 Earnings: Strong Revenue Growth and Diversified Portfolio

Jazz Pharmaceuticals reported a strong third quarter in 2025, with total revenues reaching $1.126 billion, driven by robust growth from Xywav, Epidiolex, and the successful launch of Modeyso. The company's adjusted net income (ANI) for the quarter was $501 million. Earnings per share (EPS) came in at $8.13, significantly beating estimates of $5.74. The revenue growth was largely driven by the sleep therapeutic area, with total revenue of $520 million, and Xywav net product sales growing 11% year-over-year to $431 million.

Publication Date: Nov -09

📋 Highlights
  • Record Revenue:: Q3 2025 revenue reached $1.126 billion, driven by Xywav ($431M, +11% YoY), Epidiolex ($303M, +20% QoQ), and Modeyso’s early success ($11M in first-quarter post-approval sales).
  • Revenue Guidance Narrowed:: Full-year 2025 revenue guidance updated to $4.175–4.275 billion, reflecting increased confidence in portfolio performance and execution momentum.
  • Modeyso Launch Success:: Modeyso (acquired via Chimerix) achieved $11M in sales during its first quarter post-approval, with >60% of Q3 patients new to the therapy and peak U.S. sales potential of $500M.
  • Financial Strength:: Generated $900M in cash flow YTD 2025 and ended Q3 with $2 billion in cash and investments, supporting future growth and portfolio development.
  • Product Portfolio Expansion:: FDA approvals for Zepzelca (first-line maintenance for small cell lung cancer) and Modeyso (for GEA) added to NCCN Guidelines, enhancing therapeutic differentiation and market access.

Revenue Growth and Diversification

The company's diversified portfolio continues to drive growth, with Epidiolex revenue reaching $303 million, a 20% increase from the previous quarter, driven by 10% volume growth and refined accrual rates in the US. The successful launch of Modeyso, with $11 million in sales in the first quarter following FDA approval in August, also contributed to the revenue growth. The company's oncology franchise, with approvals in frontline small cell lung cancer, high-grade gliomas, and BTC, holds promise for future growth.

Financial Performance and Guidance

Jazz Pharmaceuticals narrowed its 2025 revenue guidance to a range of $4.175 billion to $4.275 billion, reflecting increased confidence in its outlook. The company's balance sheet remains strong, with $2 billion in cash and investments at quarter end. The company's cash flow generation is also robust, with nearly $1 billion recorded for the first 9 months of 2025.

Valuation and Growth Prospects

Analysts estimate next year's revenue growth at 6.5%. The company's current valuation metrics, including a P/E Ratio of -21.6, P/S Ratio of 1.92, and EV/EBITDA of 30.0, suggest that the market is pricing in significant growth expectations. The company's diversified portfolio and successful launches of new products position it well for future growth. As Renée Galá stated, "We've delivered meaningful progress across our commercial portfolio, including the launches of Modeyso and Zepzelca, and we'll continue to focus on ensuring our therapies reach more patients quickly."

Future Outlook

The company's pipeline, including the Kv7 compound in development, also holds promise for future growth. The company's focus on areas where it can have a meaningful impact for patients, including oncology and CNS disorders, is expected to drive long-term growth. With a strong balance sheet and robust cash flow generation, Jazz Pharmaceuticals is well-positioned to execute on its strategy and create value for shareholders.

3. NewsRoom

Card image cap

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium

Dec -02

Source: prnewswire.com

Card image cap

Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec -02

Source: seekingalpha.com

Card image cap

Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner

Nov -26

Source: zacks.com

Card image cap

Here are Monday's Top Wall Street Analyst's Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More

Nov -24

Source: 247wallst.com

Card image cap

Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov -18

Source: prnewswire.com

Card image cap

JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

Nov -18

Source: zacks.com

Card image cap

Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence

Nov -17

Source: seekingalpha.com

Card image cap

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

Nov -17

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.00%)

6. Segments

Pharmaceutical Products

Expected Growth: 5.0%

Jazz Pharmaceuticals' 5.0% growth in Pharmaceutical Products is driven by increasing demand for its sleep disorder treatments, Xyrem and Sunosi, as well as growing sales of its cancer therapy, Vyxeos. Additionally, the company's strategic acquisitions and partnerships, such as its deal with PharmaMar, have expanded its product portfolio and enhanced its R&D capabilities.

7. Detailed Products

Xyrem

A sodium oxybate oral solution used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Erwinaze

A asparaginase enzyme used to treat acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase.

Vyxeos

A liposomal formulation of daunorubicin and cytarabine used to treat adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Defitelio

A defibrotide sodium injection used to treat severe hepatic veno-occlusive disease (VOD) in patients who have undergone hematopoietic stem cell transplantation.

Zygel

A transdermal cannabidiol gel used to treat Fragile X syndrome, a rare genetic disorder.

8. Jazz Pharmaceuticals plc's Porter Forces

Forces Ranking

Threat Of Substitutes

Jazz Pharmaceuticals plc has a moderate threat of substitutes due to the presence of alternative treatments and therapies for sleep disorders and oncology.

Bargaining Power Of Customers

Jazz Pharmaceuticals plc has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative suppliers.

Bargaining Power Of Suppliers

Jazz Pharmaceuticals plc has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and manufacturing services.

Threat Of New Entrants

Jazz Pharmaceuticals plc has a high threat of new entrants due to the growing demand for sleep disorders and oncology treatments, making it an attractive market for new entrants.

Intensity Of Rivalry

Jazz Pharmaceuticals plc operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 60.54%
Debt Cost 4.32%
Equity Weight 39.46%
Equity Cost 7.09%
WACC 5.41%
Leverage 153.40%

11. Quality Control: Jazz Pharmaceuticals plc passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Genmab

A-Score: 5.9/10

Value: 3.7

Growth: 9.7

Quality: 9.4

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Alkermes

A-Score: 5.2/10

Value: 4.4

Growth: 8.4

Quality: 8.9

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
ALK-Abelló

A-Score: 5.0/10

Value: 0.5

Growth: 8.2

Quality: 7.5

Yield: 0.0

Momentum: 8.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Jazz Pharmaceuticals

A-Score: 4.9/10

Value: 5.6

Growth: 7.1

Quality: 2.4

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Merus

A-Score: 3.7/10

Value: 6.0

Growth: 1.8

Quality: 4.6

Yield: 0.0

Momentum: 9.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Zealand Pharma

A-Score: 3.2/10

Value: 7.0

Growth: 2.2

Quality: 9.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

169.7$

Current Price

169.7$

Potential

-0.00%

Expected Cash-Flows